<?xml version='1.0' encoding='utf-8'?>
<document id="26626327"><sentence text="The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review."><entity charOffset="38-49" id="DDI-PubMed.26626327.s1.e0" text="fluvoxamine" /><entity charOffset="53-62" id="DDI-PubMed.26626327.s1.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.26626327.s1.e0" e2="DDI-PubMed.26626327.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26626327.s1.e0" e2="DDI-PubMed.26626327.s1.e1" /></sentence><sentence text="New clozapine optimization strategies are warranted, as some patients do not achieve sufficient response and experience various adverse effects"><entity charOffset="4-13" id="DDI-PubMed.26626327.s2.e0" text="clozapine" /></sentence><sentence text=" Fluvoxamine is a potent CYP1A2 inhibitor and may increase the ratio of clozapine to its primary metabolite N-desmethylclozapine (NDMC)"><entity charOffset="1-12" id="DDI-PubMed.26626327.s3.e0" text="Fluvoxamine" /><entity charOffset="72-81" id="DDI-PubMed.26626327.s3.e1" text="clozapine" /><entity charOffset="108-128" id="DDI-PubMed.26626327.s3.e2" text="N-desmethylclozapine" /><entity charOffset="130-134" id="DDI-PubMed.26626327.s3.e3" text="NDMC" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e0" e2="DDI-PubMed.26626327.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e0" e2="DDI-PubMed.26626327.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e0" e2="DDI-PubMed.26626327.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e0" e2="DDI-PubMed.26626327.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e1" e2="DDI-PubMed.26626327.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e1" e2="DDI-PubMed.26626327.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e1" e2="DDI-PubMed.26626327.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e2" e2="DDI-PubMed.26626327.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26626327.s3.e2" e2="DDI-PubMed.26626327.s3.e3" /></sentence><sentence text="" /><sentence text="This study aims to review all pharmacodynamic effects and the adverse effect profile of changing the clozapine/NDMC ratio with adjunctive fluvoxamine"><entity charOffset="101-110" id="DDI-PubMed.26626327.s5.e0" text="clozapine" /><entity charOffset="138-149" id="DDI-PubMed.26626327.s5.e1" text="fluvoxamine" /><entity charOffset="111-121" id="DDI-PubMed.26626327.s5.e2" text="NDMC" /><pair ddi="false" e1="DDI-PubMed.26626327.s5.e0" e2="DDI-PubMed.26626327.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26626327.s5.e0" e2="DDI-PubMed.26626327.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26626327.s5.e0" e2="DDI-PubMed.26626327.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26626327.s5.e2" e2="DDI-PubMed.26626327.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26626327.s5.e2" e2="DDI-PubMed.26626327.s5.e1" /></sentence><sentence text="" /><sentence text="MEDLINE, Embase, and the Cochrane Library were searched with the search terms &quot;clozapine&quot; and &quot;fluvoxamine&quot; without any time limit" /><sentence text=" Language was restricted to English, Scandinavian, Polish, and German" /><sentence text=" Studies were sorted for relevance based on title and abstract" /><sentence text=" Clinical recommendations of potential indications/effects were graded as level A, B, C, or D depending on studies of high, moderate, low, or very low quality, respectively" /><sentence text="" /><sentence text="Based on data from 24 case reports/series, seven cohort studies, and two randomized controlled trials, 241 patients were studied" /><sentence text=" Evidence (A) supported that adjunctive fluvoxamine increased clozapine plasma levels"><entity charOffset="40-51" id="DDI-PubMed.26626327.s13.e0" text="fluvoxamine" /><entity charOffset="62-71" id="DDI-PubMed.26626327.s13.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.26626327.s13.e0" e2="DDI-PubMed.26626327.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26626327.s13.e0" e2="DDI-PubMed.26626327.s13.e1" /></sentence><sentence text=" This may increase the probability of response in patients, where sufficient clozapine plasma levels cannot be achieved"><entity charOffset="77-86" id="DDI-PubMed.26626327.s14.e0" text="clozapine" /></sentence><sentence text=" Adjunctive fluvoxamine reduced metabolic adverse effects of clozapine (B) but not agranulocytosis risk (B)"><entity charOffset="12-23" id="DDI-PubMed.26626327.s15.e0" text="fluvoxamine" /><entity charOffset="61-70" id="DDI-PubMed.26626327.s15.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.26626327.s15.e0" e2="DDI-PubMed.26626327.s15.e0" /><pair ddi="true" e1="DDI-PubMed.26626327.s15.e0" e2="DDI-PubMed.26626327.s15.e1" /></sentence><sentence text=" Although depressive or obsessive-compulsive symptoms may improve, a SSRI with no CYP1A2 inhibition should rather be used (C)" /><sentence text=" No studies investigated the effect of adjunctive fluvoxamine to minimize clozapine rebound psychosis (D) or to reduce the effects of smoking on clozapine plasma levels (D)"><entity charOffset="50-61" id="DDI-PubMed.26626327.s17.e0" text="fluvoxamine" /><entity charOffset="74-83" id="DDI-PubMed.26626327.s17.e1" text="clozapine" /><entity charOffset="145-154" id="DDI-PubMed.26626327.s17.e2" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.26626327.s17.e0" e2="DDI-PubMed.26626327.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26626327.s17.e0" e2="DDI-PubMed.26626327.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26626327.s17.e0" e2="DDI-PubMed.26626327.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26626327.s17.e1" e2="DDI-PubMed.26626327.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26626327.s17.e1" e2="DDI-PubMed.26626327.s17.e2" /></sentence><sentence text="" /><sentence text="Adjunctive fluvoxamine may have clinical potentials for optimizing clozapine treatment but further clinical studies are warranted to explore the clinical implications"><entity charOffset="11-22" id="DDI-PubMed.26626327.s19.e0" text="fluvoxamine" /><entity charOffset="67-76" id="DDI-PubMed.26626327.s19.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.26626327.s19.e0" e2="DDI-PubMed.26626327.s19.e0" /><pair ddi="false" e1="DDI-PubMed.26626327.s19.e0" e2="DDI-PubMed.26626327.s19.e1" /></sentence><sentence text="" /></document>